Carregant...
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
We evaluated the relationship between benralizumab (30 mg every 4 and 8 weeks (Q4W, Q8W)) pharmacokinetic (PK) exposure and end points of asthma exacerbation rates (AERs) and change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV (1)) for patients with severe, uncontroll...
Guardat en:
| Publicat a: | Clin Pharmacol Ther |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767326/ https://ncbi.nlm.nih.gov/pubmed/30661249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1371 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|